Skip to main content

Belanoff Joseph K's Form 4 filing

Corcept Therapeutics Inc (CORT) · filed Mar 4, 2025

Accession no.
0000950170-25-032740
Filed
Mar 4, 2025
Trade date
Feb 28-Mar 3, 2025
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market sales total $178.1K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Belanoff Joseph KCIK 0001286199Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 3, 2025Common StockSSaleDisposed−2,924$60.91F2−$178,100.843,019,411Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 28, 2025Common StockAGrant or awardAcquired+350,000$0.00$0350,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $60.83 to $61.045 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

Remarks

The power of attorney under which this form was signed is on file with the Commission.

Read the full filing on SEC EDGAR (opens in a new tab)